Vivazome

Executive Summary

VivaZome Therapeutics is an Australian biotechnology company pioneering exosome-derived extracellular vesicle (EV) therapies for serious neuro-inflammatory conditions, including traumatic brain injury, stroke, and neurodegenerative disorders. Founded in 2020 and based in Sydney, the company leverages proprietary cell-engineering techniques and GMP-compliant manufacturing processes to produce targeted, low-immunogenic biologics with disease-modifying potential. By harnessing the natural intercellular communication properties of exosomes, VivaZome aims to address significant unmet medical needs in neurology, where current treatments are largely symptomatic rather than curative. As a preclinical-stage company, VivaZome is focused on advancing its lead programs toward first-in-human studies. Its technology platform offers the potential for improved drug delivery across the blood-brain barrier and reduced off-target effects compared to traditional biologics. However, the company faces challenges typical of early-stage biotechs, including capital requirements for clinical translation, regulatory hurdles, and competition from other EV-based therapies. With a small team and no disclosed funding rounds, execution risk remains high, though the scientific rationale and market opportunity in neuroinflammation are compelling.

Upcoming Catalysts (preview)

• Q3 2026Initiation of GLP Toxicology Studies for Lead EV Candidate70% success
• Q1 2027IND Submission for First-in-Human Trial (Traumatic Brain Injury)45% success
• TBDStrategic Partnership or Licensing Agreement with Pharma25% success